19 ottobre 2022 – On 19 October 2022, Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company, closed a USD 775 million strategic financing including (i) a USD 350 million senior secured term loan with funds managed by Pharmakon Advisors, LP, a leading investor in non-dilutive debt for the life sciences industry and the investment manager of the BioPharma Credit funds and (ii) a USD 150 million secured royalty financing with OrbiMed, a leading investor in the healthcare industry.

Walder Wyss advised the funds managed by Pharmakon Advisors, LP, BioPharma Credit and OrbiMed. The team was led by Tervel Stoyanov (Counsel, Banking & Finance) and further included Anaëlle Genoud (Associate, Banking & Finance) and Valentin Wiesner (Managing Associate, Banking & Finance).